As such, we detected that 200 and 400 ng ml−1 of soluble CXCL9, when added to the upper chamber, resulted in a highly significant fugetactic migration of Melanoma-7 (200 ng ml−1: 2.71±0.52; 400 ng ml−1: 2.16±1.03), Melanoma-17 (200 ng ml−1: 3.25±1.10; 400 ng ml−1: 4.08±1.12) and Melanoma-14 cells (200 ng ml−1: 4.12±0.53; 400 ng ml−1 3.06±1.08). The gene discussed is CXCL9; the disease is melanoma.